Acta Haematologica
Filgrastim (r-metHuG-CSF) in the 21st Century: SD/01Morstyn G.a,b · Foote M.A.a · Walker T.a · Molineux G.aaAmgen Inc., Thousand Oaks, Calif., bUCLA School of Medicine, Los Angeles, Calif., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: July 18, 2001
Issue release date: July 2001
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
Abstract
SD/01, a sustained-duration molecule, has been developed by adding a poly [ethylene glycol] molecule to the filgrastim molecule. The pegylation does not change the properties of filgrastim, except that the plasma clearance is decreased and plasma half-life is increased. Increasing the duration of the biological effects of filgrastim may offer certain groups of patients better benefits. Early clinical studies have been encouraging with no serious toxicities noted.
© 2001 S. Karger AG, Basel
Related Articles:
References
- Bodey GP, Buckley M, Sathe YS, Freierich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–340.
- Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Grous J, Picozi V, Rausch G, Smith R, Gandishar W, Yahanda A, Vincent M, Stewart M, Glaspy J: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164–170.
-
Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319–324.
-
Blackwell S, Crawford J: Filgrastim (r-metHuG-CSF) in the chemotherapy setting; in Morstyn G, Dexter TM (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, Marcel Dekker, 1994, pp 103–116.
-
Roskos LK, Cheung EN, Vincent M, Foote MA, Morstyn G: Pharmacology of filgrastim (r-metHuG-CSF); in Morstyn G, Dexter TM, Foote MA (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, Marcel Dekker, 1998, pp 51–71.
-
Osslund T, Boone T: Biochemistry and structure of filgrastim (r-metHuG-CSF); in Morstyn G, Dexter TM, Foote MA (eds): Filgrastim (r-metHuG-CSF) in Clinical Practice. New York, Marcel Dekker, 1998, pp 41–49.
- Layton JE, Hockman H, Sheridan WP, Morstyn G: Evidence for a novel in vivo control mechanism of granulopoiesis: Mature cell-related control of a regulatory growth factor. Blood 1989;74:1303–1307.
- Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G: A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724–1734.
- Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L, Yang BB, Gardner S, Miller-Messana MA, Shoemaker D, Garst J, Schwab G: Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522–2528.
- Delgado C, Francis GE, Fisher D: The uses and properties of PEG-linked proteins. Crit Rev Ther Drug Carrier Syst 1992;9:249–304.
Article / Publication Details
Published online: July 18, 2001
Issue release date: July 2001
Number of Print Pages: 5
Number of Figures: 3
Number of Tables: 0
ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)
For additional information: https://www.karger.com/AHA
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
